				1			
			1	1 1	1 1	 - 1	- 1
l		1 1		1 1	1 1		1
Reg. No	 	1 1			_		
1408. 7.10							

## **B.Tech DEGREE EXAMINATION, NOVEMBER 2023**

Seventh Semester

## 18BTE401T - CANCER BIOLOGY

(For the candidates admitted during the academic year 2020 - 2021 & 2021 - 2022)

i. Part - A should be answered in OMR sheet within first 40 minutes and OMR sheet should be handed over to

	Part - B and Part - C should be answered in answer booklet.  ime: 3 Hours		Max. Marks: 100			
PART - A $(20 \times 1 = 20 \text{ Marks})$ Answer all Questions			Mark	s BL	CO	
1.	Cancer of mesoderm origin is called(A) carcinoma (C) lymphoma	(B) sarcoma (D) myeloma	1	1	1	
2.	Transformed (cancer) cells acquire all of the (A) fail to exhibit contact inhibition and instead grow as piles of cells (C) adopt a round morphology rather than a flat or extended one	he following phenotypes except ONE  (B) can grow in conditions of low serum  (D) exhibit contact inhibition	1	2	1	
3.	An increase in cell size is termed as(A) hypertrophy (C) dysplasia	(B) hyperplasia (D) neoplasia	1	1	1	
4.	p15 and p16 inhibits one of the following (A) Cyclin D (C) Cyclin B	cyclin (B) Cyclin C (D) Cyclin A	. 1	1	1	
5.	Which one of the following is NOT a mo (A) RAS	lecular "sensor" of DNA damage? (B) ATM	1	2	2	

7	The interaction between genes an	d environment is called	1	1	2
7.	(A) ecogenetics (C) molecular genetics	<ul><li>(B) epigenetics</li><li>(D) meta-genetics</li></ul>			
8.	One of the following is an examp	ole of a DNA-intercalating agent.  (B) cisplatin	1	1	2

(D) ATR

(B) base excision repair (BER)

(D) homologous recombination (HR)

Repair of DNA adducts resulting from platinum-based chemotherapy is achieved

2 (B) cisplatin (A) adriamycin (D) carboplatin (C) cyclophosphamide

Active form of RAS is converted into inactive RAS by (B) GNEF (A) GAP (D) DEP (C) GEP 10. Homo-oligomeric complexes resulting in autophosphorylation of tyr177 and thus 2

activating a nuclear tyrosine kinase is due to (B) v-abl (A) BCR-ABL

(D) v-cis (C) Carboxylation

3

2

(C) DNA-PK

(A) mismatch repair (MMR)

(C) nucleotide excision repair (NER)

through

Note:

11	is one modification required for localizing Ras to the membrane	1	2	3
	(A) Farnesylation (B) Adenylation (C) Acetylation (D) Carboxylation	•	-	,
12	(A) oncogene (C) promotor (D) tumor suppressor	1	1	4
13.	CXCL12 is also known as (A) SDF-1α (B) SDF-1β	1	1	4
1.4	(C) TGF-1 $\alpha$ (D) PDF-1 $\alpha$			9
14.	Formation of new blood vessels from angioblasts or progenitor stem cells is called	1	1	4
	(A) vasculogenesis (B) metastasis (C) angiogenesis (D) neoplasia			
15.	EGF receptor that does not contain a tyrosine kinase domain is (A) HER3 (B) HER2 (C) HER4 (D) HER1	1	2	5
16.	STAT dimerization is mediated by upon binding of the cytokine to its receptor.  (A) JAK  (B) MAPK  (C) TNF  (D) TGF	Hencel	1	5
	Local therapy for cancer includes one of the following.  (A) surgery  (B) chemotherapy  (C) hormonal therapy  (D) monoclonal antibodies	1	2	5
18.	The first patient treated with the linear accelerator (radiation therapy) for retinoblastoma in 1957 is  (A) Gordon Isaacs  (B) Gordon John  (C) Gordon Mathew  (D) Gary Wildey	1	1	6
19.	Molecular imaging techniques which involve using molecular imaging probes to detect biological molecules in living subjects include all of the following except ONE	1	2	6
	(A) X-ray (B) SPECT (C) MRI (D) PET			
	Vitaxin is a Mab against ανβ3 (A) humanized (B) Rabit (C) Horse (D) Rat	1	2	6
	PART - B $(5 \times 4 = 20 \text{ Marks})$ Answer any 5 Questions	Mark	s BL	CO
21.	List a short note on therapeutic strategies of cyclin/cdk.	4	3	1
22.	Explain about principles of conventional cancer therapies	4	3	2
	3. With a neat diagram explain about upstream and downstream effects of NF-kB.			3
	4. Summarize a short note on methylation in cancer.			4
25.	5. With a neat diagram, explain about paradoxical roles of TGFβ.			5
26. Outline the diseases associated with angiogenesis.			1	6
27.	List down the complication of chemotherapy.	4	2	6
	PART - C (5 × 12 = 60 Marks) Answer all Ouestions	Mark	s BL	CO

28.	(a) Explain about the structure, function and regulation of p53.  (OR)	12	1	Ţ
	(b) Illustrate the roles of pRb, myc and TGF-B in influencing cell cycle.			
29.	(a) Compare the six major DNA repair pathways. (OR)	12	1	2
	(b) Discuss about therapeutic targets of epigenome.			
30.	(a) Describe the role of cancer stem cells and pathways involved in this process.  (OR)	12	3	3
	(b) Organize the key factors and mechanisms involved in immune reactivity to tumors.			
31.	(a) Write about prolactin-R signaling and pathway cross-talk in cancer (OR)	12	3	4
	(b) Illustrate tumor micro-environment and explain how it promotes cancer growth?			
32.	(a) Categorize the non-pharmacological therapy of neuropathic cancer pain.	12	3	6
	(OR)  (b) Write about mechanisms of actions of chemotherapeutic drugs in neoplastic disease	ř		

\*\*\*\*

#